Academic Journal
Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.
| Τίτλος: | Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. |
|---|---|
| Συγγραφείς: | Kus T; Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. drtulaykus83@hotmail.com., Aktas G; Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey., Alpak G; Department of Psychiatry, University of Gaziantep, TR-27310, Gaziantep, Turkey., Kalender ME; Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey., Sevinc A; Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey., Kul S; Department of Biostatistics, Faculty of Medicine, University of Gaziantep, TR-27310, Gaziantep, Turkey., Temizer M; Department of Public Health, University of Gaziantep, TR-27310, Gaziantep, Turkey., Camci C; Department of Internal Medicine, Division of Medical Oncology, Gaziantep Oncology Hospital, University of Gaziantep, TR-27310, Gaziantep, Turkey. |
| Πηγή: | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 May; Vol. 24 (5), pp. 2085-2091. Date of Electronic Publication: 2015 Nov 07. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Berlin : Springer International, c1993- |
| Ιατρικοί όροι (MeSH): | Antineoplastic Agents/*adverse effects , Bridged-Ring Compounds/*adverse effects , Neoplasms/*drug therapy , Neurotoxicity Syndromes/*prevention & control , Organoplatinum Compounds/*adverse effects , Selective Serotonin Reuptake Inhibitors/*therapeutic use , Taxoids/*adverse effects , Venlafaxine Hydrochloride/*therapeutic use, Bridged-Ring Compounds/administration & dosage ; Neoplasms/complications ; Neoplasms/psychology ; Neurotoxicity Syndromes/diagnosis ; Neurotoxicity Syndromes/psychology ; Organoplatinum Compounds/administration & dosage ; Taxoids/administration & dosage ; Activities of Daily Living ; Adult ; Aged ; Case-Control Studies ; Female ; Humans ; Middle Aged ; Oxaliplatin ; Quality of Life ; Retrospective Studies ; Treatment Outcome |
| Περίληψη: | Background: Oxaliplatin and taxane-induced neurosensory toxicity is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute neuropathy with venlafaxine treatment during the chemotherapy period. Patients and Methods: In this retrospective case-control study, from January 2010 to February 2015, patients who experienced treatment with oxaliplatin and taxane-induced acute neurotoxicity were evaluated according to the NCI-CTCAE v. 4.03 grading scale. Neurotoxicity was evaluated using a numeric rating scale (NRS) for pain intensity and experienced relief under the treatment of venlafaxine and using a neuropathic pain symptom inventory scale (NPSI) for the style of complaints. Patients who were diagnosed as mildly depressed according to the HOST anxiety and depression scale and who had grade 1 to 3 sensory neurotoxicity based on the NCI-CTCAE v. 4.03 grading scale, and who also reported ≥ 4/10 on a NRS were eligible. The primary end point was the rate of more than 75 % symptomatic relief under venlafaxine treatment. Results: Two hundred six patients were included (82 % female, median age: 52.7 years). Most patients had breast, gynecologic, and colon cancer (93.4 %). Ninety-one patients who received venlafaxine and 115 patients as the control group were assessed for neurotoxicity every 3 weeks. Based on the NRS, a rate of more than 75 % symptomatic relief was 53.5, 58.3, and 45.2 % in venlafaxine arm versus 0, 0, and 0 % in the control arm in the first, second, and third visits, respectively. Side-effects of venlafaxine (n = 7) were grade 1-2 nausea/vomiting (3.2 %) and asthenia/somnolence (3.2 %) without grade 3-4 events. Conclusion: Venlafaxine has a significant clinical activity against taxane-oxaliplatin-induced acute neurosensory toxicity. |
| References: | Pharmacogenet Genomics. 2009 Dec;19(12):979-83. (PMID: 21151855) Cancer. 2008 Jun 15;112(12):2802-8. (PMID: 18428211) Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. (PMID: 19059298) J Pain. 2012 Mar;13(3):276-84. (PMID: 22325298) Pharmacology. 2013;91(1-2):69-76. (PMID: 23183148) Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15. (PMID: 8102012) J Neurophysiol. 2001 May;85(5):2293-7. (PMID: 11353042) Diabetes Care. 1999 Nov;22(11):1909-10. (PMID: 10546032) J Clin Oncol. 2011 Feb 1;29(4):421-7. (PMID: 21189381) Breast Cancer. 2004;11(1):82-5. (PMID: 14718798) Ann Oncol. 2012 Jan;23(1):200-205. (PMID: 21427067) Anticancer Res. 2009 Jul;29(7):2601-6. (PMID: 19596934) BMC Cancer. 2012 Aug 15;12:355. (PMID: 22894640) Sao Paulo Med J. 2013;131(1):35-8. (PMID: 23538593) J Clin Oncol. 2014 Apr 1;32(10):997-1005. (PMID: 24297951) Cancer. 2007 Nov 1;110(9):2110-8. (PMID: 17853395) Pain. 2004 Apr;108(3):248-257. (PMID: 15030944) JAMA. 2013 Apr 3;309(13):1359-67. (PMID: 23549581) Pharmacotherapy. 2004 May;24(5):621-9. (PMID: 15162896) |
| Contributed Indexing: | Keywords: Docetaxel; Neurotoxicity; Oxaliplatin; Paclitaxel; Venlafaxine |
| Substance Nomenclature: | 0 (Antineoplastic Agents) 0 (Bridged-Ring Compounds) 0 (Organoplatinum Compounds) 04ZR38536J (Oxaliplatin) 0 (Selective Serotonin Reuptake Inhibitors) 0 (Taxoids) 7D7RX5A8MO (Venlafaxine Hydrochloride) 1605-68-1 (taxane) |
| Entry Date(s): | Date Created: 20151108 Date Completed: 20161220 Latest Revision: 20261011 |
| Update Code: | 20261011 |
| DOI: | 10.1007/s00520-015-3009-x |
| PMID: | 26546457 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1433-7339 |
|---|---|
| DOI: | 10.1007/s00520-015-3009-x |